Daawaynta kansarka ganaca ee uu keeno korona

Daawaynta kansarka ganaca ee uu keeno korona

Saynis yahanadu waxa ay horumar ka gaadheen samaynta talaalka ka hortaga kansarka kadib markii ay isticmaaleen isla tignoolajiyada loo isticmaalo samaynta talaalka fayraska Corona, taas oo ay samaysay shirkada Piontech-Pfizer, talaalkan oo si gaar ah loogu talagaly bukaan kasta waxa uu kicin karaa habka difaaca si uu u weeraro unugyada kansarka.

Khubarada ka dambeysa horumarinta tallaalka Pfizer ayaa la kaashaday dhakhaatiirta magaalada New York si ay u soo saaraan tallaal loogu talagalay bukaannada kansarka xameetida, sida uu sheegay wargeyska Ingiriiska, "The Telegraph".

Natiijooyinka tijaabada bukaan-socodka ee wajiga I, oo ah kii ugu horreeyay ee noociisa ah, ayaa lagu dhawaaqay usbuucan dhamaadkii shirkii sanadlaha ah ee Bulshada Mareykanka ee Oncology Clinic (ASCO) ee Chicago.

Saynis yahanadu waxay rajaynayaan in natiijadu ay soo bandhigto waa cusub oo lagu daweynayo kansarrada kale ee ay adagtahay in la daweeyo, maadaama kansarka beeryaradu inta badan loo yaqaan "ilmaha boodhka" ee burooyinka dilaaga ah.

Habka ficilka tallaalka

Iyo faahfaahinta tijaabada, ayaa lagu maray labaatan bukaan oo qaba adenocarcinoma pancreatic (PDAC), taas oo u dhiganta 90% dhammaan kiisaska kansarka ganaca, tijaabada.

Bukaanadan ayaa lagu sameeyay qaliin lagaga saaray kansarka, waxaana 72 saacadood kadib muunadooda burada loo raray BioNTech ee Jarmalka si loogu daweeyo iyo tallaalka shaqsiga ah, kaas oo xididada laga siiyo bukaanka.

Bukaanku waxa kale oo ay heleen immunotherapy si ay uga caawiso kor u qaadida jawaabahooda.

Tallaabooyinka tallaalka Corona

Tallaalka cusubi waxa ay adeegsadaan mRNA, oo ah koodka hidde-sidaha ee buro, si ay u baraan unugyada jidhka si ay u sameeyaan borootiinka kicinaya jawaabta difaaca, isla tignoolajiyada loo isticmaalo tallaalada Corona ee ay soo saartay shirkadda Pfizer-BioNTech.

Jirku wuxuu markaa bartaa in unugyada kansarku ay dhab ahaantii shisheeye yihiin wuxuuna u soo diraa unugyada T si ay u raadiyaan oo u dilaan haddii ay soo noqdaan.

natiijooyin rajo leh

Lix iyo toban bukaan ayaa helay tallaalka ugu horreeya sagaal toddobaad qalliinka ka dib, kala badh kuwan waxay soo saareen jawaab difaac oo muhiim ah.

Sidoo kale, dhammaan siddeedda bukaan waxay ahaayeen kuwo aan kansar lahayn 18 bilood, iyagoo soo jeedinaya in unugyada T ee uu hawlgeliyay tallaalku ay joojiyaan kansarka soo noqnoqda.

Si kastaba ha ahaatee, siddeed bukaan ayaan ka jawaabin tallaalka, halka lix ay arkeen kansarkoodii soo noqnoqda ka dib hal sano ka dib, cilmi-baarayaashu waxay weli baarayaan sababta kala bar kooxda aysan uga jawaabin.

Prof Ozlem Turise, oo ah aasaasaha iyo agaasimaha caafimaadka ee BioNTech, ayaa sheegay in kaliya boqolkiiba shan bukaanada qaba kansarka ganaca ay ka jawaabaan daaweynta.

"Waxaa naga go'an inaan ka gudubno caqabadan annagoo dhisnayna cilmi-baarista aan muddada dheer ku sameynayno tallaallada kansarka oo aan isku dayno inaan jebinno waddo cusub oo lagu daweynayo burooyinkan ay adag tahay in la daweeyo," ayay raacisay.